Ulrich: "The fast-growing business of SUMO chains." in: Molecular cell, Vol. 32, Issue 3, pp. 301-5, (2008) (PubMed).
Saitoh, Uchimura, Tachibana, Sugahara, Saitoh, Nakao: "In situ SUMOylation analysis reveals a modulatory role of RanBP2 in the nuclear rim and PML bodies." in: Experimental cell research, Vol. 312, Issue 8, pp. 1418-30, (2006) (PubMed).
Cheng, Bawa, Lee, Gong, Yeh: "Role of desumoylation in the development of prostate cancer." in: Neoplasia (New York, N.Y.), Vol. 8, Issue 8, pp. 667-76, (2006) (PubMed).
Uchimura, Ichimura, Uwada, Tachibana, Sugahara, Nakao, Saitoh: "Involvement of SUMO modification in MBD1- and MCAF1-mediated heterochromatin formation." in: The Journal of biological chemistry, Vol. 281, Issue 32, pp. 23180-90, (2006) (PubMed).
Target
SUMO1
(Small Ubiquitin Related Modifier Protein 1 (SUMO1))
SUMO (Small Ubiquitin-like Modifier) proteins are a family of small proteins that are covalently attached to and detached from other proteins in cells to modify their function. Unlike ubiquitination, which targets proteins for degradation, SUMO modification plays a critical role in a number of cellular functions including nucleocytoplasmic transport, gene expression, cell cycle and formation of subnuclear structures such as promyelocytic leukemia (PML) bodies. There are three confirmed SUMO isoforms in human, SUMO1, SUMO2 and SUMO3. SUMO2 /3 show a high degree of similarity to each other and are distinct from SUMO-1. Individual SUMO family members are all targeted to different proteins with diverse biological functions. SUMO-1 is conjugated to RanGAP, PML, p53 and IkappaB-alpha to regulate nuclear trafficking, formation of subnuclear structures, regulation of transcriptional activity and protein stability. SUMO1 is encoded as a 101 aa protein and first Met and C-terminal 4 aa are removed from the preprotein.